AMSTERDAM, May 9, 2023 /PRNewswire/ -- Freya Pharma Solutions, a pharmaceutical company focusing on the development of effective pharmaceutical therapies for women diagnosed with Female Sexual Disorders (FSD), announced today that the United States (US) Food and Drug Administration (FDA) has informed Freya that they will provide a written response by 4 June on the request for advice on the US Clinical Development Program of Lybrido™ for the treatment of Female Sexual Interest/Arousal Disorder (FSIAD).
AMSTERDAM, March 8, 2023 /PRNewswire/ -- Freya Pharma Solutions, a late clinical stage company focusing on the development of effective pharmaceutical therapies for women diagnosed with Female Sexual Disorders (FSD), announced today the appointment of Christa van Kan, MSc (picture below) to the position of Director Clinical Operations, starting in March 2023. Ms. van Kan brings more than 25 years of clinical operations and trial management experience to Freya Pharma Solutions.
AMSTERDAM, Feb. 22, 2023 /PRNewswire/ -- Freya Pharma Solutions, a late clinical stage company focusing on the development of effective pharmaceutical therapies for women diagnosed with Female Sexual Disorders (FSD), announced today that participants of the European Society for Sexual Medicine (ESSM) Congress, held 16 – 18 February, 2023, in Rotterdam, The Netherlands, showed great interest in Freya's innovative drug candidate LybridoTM.
AMSTERDAM, Feb. 10, 2023 /PRNewswire/ -- Freya Pharma Solutions, a late clinical stage company focusing on the development of effective pharmaceutical therapies for women diagnosed with Female Sexual Disorders (FSD), today announced the extension of its Scientific Advisory Board (SAB) with four independent leading medical scientists in the FSD field from the US: Dr. Irwin Goldstein, Sue Goldstein, Prof. Sheryl Kingsberg, and Dr. Rachel Rubin. The extension was established in the light of the start of preparations for Freya's clinical development program for Lybrido™ against Female Sexual Disorders in the United States. The first meeting with the new members took place on 4 February 2023 in Houston, US. The SAB is chaired by Freya's Chief Medical Officer Dr. Jan van der Mooren.
AMSTERDAM, Feb. 2, 2023 /PRNewswire/ -- Freya Pharma Solutions, a late clinical stage company focusing on the development of effective pharmaceutical therapies for women who have been diagnosed with Female Sexual Interest/Arousal Disorder (FSIAD), today announced the appointment of Nicole Hijnen, PhD (picture below) as President of Freya's Board as per January 2023. Dr. Hijnen is a health scientist who held a variety of senior management positions within Philips Healthtech, most recently as Director - Business Leader Connected Care Benelux. Her appointment comes in a year where Freya is rolling out its final clinical development program, starting with the confirmatory ALETTA clinical trial with Lybrido™ in premenopausal women with acquired FSIAD.
AMSTERDAM, Nov. 4, 2022 /PRNewswire/ -- Freya Pharma Solutions, a late clinical stage pharmaceutical company focusing on the development of effective pharmaceutical therapies for women diagnosed with Female Sexual Interest/Arousal Disorder (FSIAD), has presented the design of its upcoming ALETTA pivotal clinical trial with Lybrido™ at the 23rd ISSM/SMSNA Scientific Meeting. The International Society for Sexual Medicine (ISSM) Scientific Meeting & 23rd Annual Fall Scientific Meeting of Sexual Medicine Society of North America (SMSNA), was held late October 2022 in Miami Beach, Florida. The paper titled 'Design of the ALETTA Clinical Study: A Randomized Double-Blind Placebo-Controlled Study investigating the Efficacy and Safety of Lybrido™ in Premenopausal Women with Acquired FSIAD', was presented by first author Dr. Cobi Reisman and got a warm scientific reception by attending health professionals from all over the world.
After more than a decade in development, Freya Pharma Solutions plans to advance an oral tablet dubbed Lybrido into Phase III trials to treat female sexual interest/arousal disorder (FSIAD).
AMSTERDAM, Sept. 28, 2022 /PRNewswire/ -- Freya Pharma Solutions, a late clinical stage pharmaceutical company focusing on the development of effective pharmaceutical therapies for women diagnosed with Female Sexual Interest/Arousal Disorder (FSIAD), today announced the receipt of early European Medicines Agency (EMA) scientific advice on its upcoming pivotal phase 3 clinical trial (the ALETTA trial), investigating Lybrido for the treatment of FSIAD. The EMA Committee for Medicinal Products for Human Use (CHMP) came to its conclusions within the short, 40-day evaluation phase, without necessitating a discussion meeting for further clarification. Freya will now implement the adjustments as recommended by EMA in its clinical development program for Lybrido.
Freya Pharma Solutions, a late clinical stage pharmaceutical company focusing on the development of effective pharmaceutical therapies for women...
Freya Pharma Solutions, a late clinical stage pharmaceutical company focusing on the development of effective pharmaceutical therapies for women...